Targeting channel in cell lysosome could selectively kill cancer cells
Activating the protein channel TRPML1 induced selective melanoma cell death while sparing normal cells, suggesting a potential pathway for new cancer therapies.
List view / Grid view
Activating the protein channel TRPML1 induced selective melanoma cell death while sparing normal cells, suggesting a potential pathway for new cancer therapies.
A major limitation in drug development is the occurrence of drug-candidate toxicity during clinical research. This may occur because tumour-derived cell lines are limited as a pre-clinical model – in part because of an altered metabolic poise. A recent study has revealed a profound plasticity in gene expression and metabolic poise that can…
In this article, we outline three recent studies that have advanced the potential uses of CRISPR in the biomedical field.
Scientists show that an antibody targeting a protein acting as a viral toxin, can prevent the dengue virus from infecting human cells.
Researchers have discovered that in mice with cancers in the liver, immunotherapy and radiotherapy prevented T-cell death.
The synthetic protein nanoparticle can cross the blood-brain barrier and deliver a targeted therapeutic to glioblastoma cells, say researchers.
Scientists used high throughput screening (HTS) to identify molecules that protect against cellular stress in murine skin cells.
Researchers have revealed that the antibiotic concanamycin A targets a protein called Nef, allowing the immune system to destroy HIV in cells.
A drug-like compound that can inhibit a key family of enzymes associated with several types of cancer has been developed and tested successfully in cells.
Researchers have treated diffuse intrinsic pontine glioma (DIPG), a fatal childhood brain cancer, in mice by targeting two metabolic pathways.